← Back to Screener
XBiotech Inc (XBIT)
Price$2.51
Favorite Metrics
Price vs S&P 500 (26W)-11.90%
Price vs S&P 500 (4W)-6.56%
Market Capitalization$78.32M
All Metrics
Book Value / Share (Quarterly)$4.60
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.32
Price vs S&P 500 (YTD)-1.21%
Gross Margin (TTM)83.79%
Net Profit Margin (TTM)-820.45%
EPS (TTM)$-1.49
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1.49
EPS (Annual)$-1.30
ROI (Annual)-20.26%
Gross Margin (Annual)83.79%
Cash / Share (Quarterly)$4.12
ROA (Last FY)-19.59%
EBITD / Share (TTM)$-1.72
ROE (5Y Avg)-11.20%
Operating Margin (TTM)-860.10%
Cash Flow / Share (Annual)$-1.32
P/B Ratio0.56x
P/B Ratio (Quarterly)0.51x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-11.78x
Net Interest Coverage (TTM)-105.08x
ROA (TTM)-26.67%
EV / EBITDA (TTM)-0.07x
EPS Incl Extra (Annual)$-1.30
Current Ratio (Annual)16.01x
Quick Ratio (Quarterly)15.88x
3-Month Avg Trading Volume0.04M
52-Week Price Return-16.89%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)19.53x
Asset Turnover (Annual)0.02x
52-Week High$3.61
EPS Excl Extra (Annual)$-1.30
CapEx CAGR (5Y)-40.04%
26-Week Price Return-3.15%
Quick Ratio (Annual)15.88x
13-Week Price Return-5.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.01x
Enterprise Value$-47.233
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-17.30%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-837.66%
Cash / Share (Annual)$4.12
3-Month Return Std Dev34.14%
Net Income / Employee (TTM)$-1
ROE (Last FY)-21.40%
Net Interest Coverage (Annual)-3.98x
EPS Basic Excl Extra (Annual)$-1.30
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.49
Receivables Turnover (Annual)0.00x
ROI (TTM)-27.80%
P/S Ratio (TTM)19.53x
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-51.99%
Year-to-Date Return2.93%
5-Day Price Return2.07%
EPS Normalized (Annual)$-1.30
ROA (5Y Avg)-10.66%
Net Profit Margin (Annual)-820.45%
Month-to-Date Return4.68%
EBITD / Share (Annual)$-1.24
Operating Margin (Annual)-860.10%
ROI (5Y Avg)-10.97%
EPS Basic Excl Extra (TTM)$-1.49
P/B Ratio (Annual)0.51x
Pretax Margin (TTM)-837.66%
Book Value / Share (Annual)$4.60
Price vs S&P 500 (13W)-8.61%
Beta0.84x
P/FCF (Annual)1.19x
Revenue / Share (TTM)$0.00
ROE (TTM)-27.80%
52-Week Low$2.09
Analyst Recommendations
Sep 2021
Oct 2021
Nov 2021
Dec 2021
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XBITXBiotech Inc | 19.53x | — | 83.79% | — | $2.51 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
XBiotech is a clinical-stage biopharmaceutical company developing monoclonal antibodies using its proprietary True Human technology platform. The company focuses on anti-inflammatory therapeutic antibodies, primarily for oncology applications. All operations are based in the United States.